843 related articles for article (PubMed ID: 32270713)
1. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
[No Abstract] [Full Text] [Related]
2. GNRI And Conut Scores: Simple Predictors of Sarcopenia in Metastatic Colorectal Cancer Patients.
Güç ZG; Altay C; Özgül HA; Ellidokuz H; Yavuzşen T
Support Care Cancer; 2022 Oct; 30(10):7845-7852. PubMed ID: 35716261
[TBL] [Abstract][Full Text] [Related]
3. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Prognostic Abilities Among Preoperative Laboratory Data Indices in Patients with Resectable Gastric and Esophagogastric Junction Adenocarcinoma.
Urabe M; Yamashita H; Watanabe T; Seto Y
World J Surg; 2018 Jan; 42(1):185-194. PubMed ID: 28741195
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of a predictive model comprising preoperative inflammatory response and nutritional indexes in patients with gastric cancer].
Wu LL; Cai MZ; Wang BG; Deng JY; Ke B; Zhang RP; Liang H; Wang XN
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):680-688. PubMed ID: 37583026
[No Abstract] [Full Text] [Related]
6. Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer.
Takamizawa Y; Shida D; Boku N; Nakamura Y; Ahiko Y; Yoshida T; Tanabe T; Takashima A; Kanemitsu Y
BMC Cancer; 2020 Nov; 20(1):1092. PubMed ID: 33176752
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
Liu Y; Chen S; Zheng C; Ding M; Zhang L; Wang L; Xie M; Zhou J
BMC Cancer; 2017 Apr; 17(1):285. PubMed ID: 28431566
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of prognostic nutritional index in patients with advanced gastric cancer].
Song S; Liu H; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Feb; 21(2):180-184. PubMed ID: 29492917
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?
Dogan M; Algin E; Guven ZT; Baykara M; Kos TF; Bal O; Zengin N
Curr Med Res Opin; 2018 May; 34(5):857-863. PubMed ID: 29161926
[TBL] [Abstract][Full Text] [Related]
11. The Relationship Between Preoperative Systemic Immune Inflammation Index and Prognostic Nutritional Index and the Prognosis of Patients With Alveolar Hydatid Disease.
Ren B; Chen X; Lei P; Hou L; Wang H; Zhou Y; Ren L; Fan H; Wang Z; Yuan J
Front Immunol; 2021; 12():691364. PubMed ID: 34248983
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer.
Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
Lung Cancer (Auckl); 2017; 8():249-257. PubMed ID: 29263709
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
[TBL] [Abstract][Full Text] [Related]
15. Novel immunological and nutritional-based prognostic index for gastric cancer.
Sun KY; Xu JB; Chen SL; Yuan YJ; Wu H; Peng JJ; Chen CQ; Guo P; Hao YT; He YL
World J Gastroenterol; 2015 May; 21(19):5961-71. PubMed ID: 26019461
[TBL] [Abstract][Full Text] [Related]
16. Preoperative sarcopenia combined with prognostic nutritional index predicts long-term prognosis of radical gastrectomy with advanced gastric cancer: a comprehensive analysis of two-center study.
Han Y; Wu J; Ji R; Tan H; Tian S; Yin J; Xu J; Chen X; Liu W; Cui H
BMC Cancer; 2023 Aug; 23(1):751. PubMed ID: 37580693
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia.
Ruan GT; Xie HL; Yuan KT; Lin SQ; Zhang HY; Liu CA; Shi JY; Ge YZ; Song MM; Hu CL; Zhang XW; Liu XY; Yang M; Wang KH; Zheng X; Chen Y; Hu W; Cong MH; Zhu LC; Deng L; Shi HP
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2813-2823. PubMed ID: 37902006
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer.
Wang DS; Luo HY; Qiu MZ; Wang ZQ; Zhang DS; Wang FH; Li YH; Xu RH
Med Oncol; 2012 Dec; 29(5):3092-100. PubMed ID: 22476808
[TBL] [Abstract][Full Text] [Related]
19. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
[TBL] [Abstract][Full Text] [Related]
20. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.
Hacker UT; Hasenclever D; Baber R; Linder N; Busse H; Obermannova R; Zdrazilova-Dubska L; Valik D; Lordick F
Ann Oncol; 2022 Jul; 33(7):685-692. PubMed ID: 35395383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
